Shukra Pharmaceuticals working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY24Mar 2024FY23Mar 2023
1,130.14×—
133.86×187.28×
8,566.66×—
−7,302.66×—
0.98×0.78×
−0.28×0.72×
−0.27×0.59×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SHUKRAPHAR₹75.06

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOCMcap ₹60.5 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Inventory Days (DIO)—1,130.14
Receivable Days (DSO)187.28133.86
Payable Days (DPO)—8,566.66
Cash Conversion Cycle (days)—-7,302.66
Asset Turnover0.780.98
Cash Conversion (CFO/Net Income)0.72-0.28
CFO/EBITDA0.59-0.27
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.